organization · Reporting owner
Boston Foundation, Inc.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Decoy Therapeutics Inc.
Report date December 31, 2018 · Filed February 05, 2019
Section 16 reporting ended · disclosed 2019-02-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | Direct | 2,200,000 |
Reported balance
After 2019-01-30 transaction · row 1
1 source rowRow 1 · 2019-01-30 · Sale · Disposed 1,600,000 · Balance 2,200,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 30, 2019 Filed Feb 5, 2019 15:03 UTC | Decoy Therapeutics Inc. FLKS · Entity 937 | SaleCommon Stock, par value $0.0001 | 1,600,000 | $0.33 | $521,600.00 |
DisclosureSEC source: 0001762003-19-000004 · primary_doc.xml · nonDerivative · entry 1 Boston Foundation, Inc. · CIK 0001762003 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,200,000 Read SEC document |
| January 09, 2019 Filed Jan 10, 2019 14:48 UTC | Decoy Therapeutics Inc. FLKS · Entity 937 | SaleCommon Stock, par value $0.0001 | 337,000 | $0.37 | $123,847.50 |
DisclosureSEC source: 0001762003-19-000002 · primary_doc.xml · nonDerivative · entry 1 Boston Foundation, Inc. · CIK 0001762003 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,600,000 Read SEC document |
| January 08, 2019 Filed Jan 9, 2019 16:26 UTC | Decoy Therapeutics Inc. FLKS · Entity 937 | SaleCommon Stock, par value $0.0001 | 263,000 | $0.40 | $104,305.80 |
DisclosureSEC source: 0001762003-19-000001 · primary_doc.xml · nonDerivative · entry 1 Boston Foundation, Inc. · CIK 0001762003 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,937,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.